No Data
No Data
No Data
*ST Longjin: 2024 performance forecast
*Special Treat Longjin (002750.SZ): Expected loss of 29.8162 million yuan to 44.3776 million yuan for the year 2024.
*ST Longjin (002750.SZ) announced its performance forecast for 2024 on January 21. The total loss for 2024 is expected to be between 33.2562 million yuan and 49.4976 million yuan. The Net income attributable to shareholders of the listed company is expected to be a loss of between 29.8162 million yuan and 44.3776 million yuan. The Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be a loss of between 38.0034 million yuan and 56.5632 million yuan. The basic EPS is expected to be a loss of between 0.0744 yuan/share and 0.1108 yuan/share, with revenue expected to be between 50.865 million yuan and 74 million yuan.
*Special Treat Longjin (002750.SZ): The holding subsidiary has obtained the Pharmaceutical registration certificate.
On January 3, Glonghui reported that *ST Longjin (002750.SZ) announced that its holding subsidiary Yunnan Longjin Kangyou Biomedical Co., Ltd. recently received the drug registration certificate for Ezetimibe tablets issued by the National Medical Products Administration (Certificate No.: 2024S30289). Ezetimibe tablets are cholesterol absorption inhibitors, initially developed in collaboration with Merck and Schering-Plough, and were approved for import into China in 2006. The original research compound patent in China expired in 2022, and it is mainly used clinically to treat primary hypercholesterolemia and homozygous familial hypercholesterolemia.
Special treat Longjin (002750.SZ): Received the pharmaceutical registration certificate for sildenafil citrate orally disintegrating tablets.
*ST Longjin (002750.SZ) announced that the company's controlling subsidiary yunnan Longjin Kangyou Biomedical Co., Ltd.
*ST Longjin: 2024 Third Quarter Report
*ST Longjin: 2024 Semi-Annual Report Summary